FDx Advisors Inc. Buys New Position in Emergent Biosolutions Inc (EBS)
FDx Advisors Inc. bought a new stake in shares of Emergent Biosolutions Inc (NYSE:EBS) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 13,541 shares of the biopharmaceutical company’s stock, valued at approximately $629,000.
A number of other hedge funds have also added to or reduced their stakes in the business. Ameritas Investment Partners Inc. grew its position in shares of Emergent Biosolutions by 23.2% during the second quarter. Ameritas Investment Partners Inc. now owns 3,118 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 587 shares during the last quarter. First Quadrant L P CA bought a new position in shares of Emergent Biosolutions during the third quarter worth about $157,000. LS Investment Advisors LLC grew its position in shares of Emergent Biosolutions by 183.0% during the fourth quarter. LS Investment Advisors LLC now owns 3,948 shares of the biopharmaceutical company’s stock worth $183,000 after acquiring an additional 2,553 shares during the last quarter. Victory Capital Management Inc. bought a new position in shares of Emergent Biosolutions during the third quarter worth about $191,000. Finally, GW&K Investment Management LLC bought a new position in shares of Emergent Biosolutions during the fourth quarter worth about $200,000. Hedge funds and other institutional investors own 78.23% of the company’s stock.
EBS has been the subject of several recent research reports. Zacks Investment Research upgraded shares of Emergent Biosolutions from a “hold” rating to a “strong-buy” rating and set a $53.00 price target for the company in a research report on Tuesday, January 2nd. Goldman Sachs Group initiated coverage on shares of Emergent Biosolutions in a research report on Wednesday, January 24th. They set a “neutral” rating and a $55.00 price target for the company. Chardan Capital upped their price target on shares of Emergent Biosolutions from $47.00 to $53.00 and gave the stock a “buy” rating in a research report on Tuesday, January 16th. Singular Research upped their price target on shares of Emergent Biosolutions from $45.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, ValuEngine upgraded shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a research report on Thursday. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $52.80.
Shares of Emergent Biosolutions Inc (NYSE:EBS) opened at $49.67 on Friday. The firm has a market cap of $2,437.61, a PE ratio of 29.39, a P/E/G ratio of 0.99 and a beta of 1.26. Emergent Biosolutions Inc has a 1-year low of $27.94 and a 1-year high of $51.25. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.85 and a quick ratio of 3.42.
Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported $0.74 earnings per share for the quarter, topping the consensus estimate of $0.70 by $0.04. The business had revenue of $193.80 million during the quarter, compared to the consensus estimate of $189.96 million. Emergent Biosolutions had a net margin of 14.73% and a return on equity of 13.66%. The company’s quarterly revenue was up 27.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.74 earnings per share. analysts forecast that Emergent Biosolutions Inc will post 2.27 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was first published by Daily Political and is owned by of Daily Political. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.dailypolitical.com/2018/03/03/fdx-advisors-inc-buys-new-position-in-emergent-biosolutions-inc-ebs.html.
About Emergent Biosolutions
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.